Shenzhen NewDEL Biotech Co., Ltd. specializes in innovative drug development, focusing on small molecule therapies for diseases such as cancer, autoimmune disorders, and neurological conditions. The company has established a proprietary DNA-encoded compound library (DEL) platform, which enables efficient drug discovery through a unique combination of high-throughput screening and combinatorial chemistry. This platform boasts a molecular library containing over 100 billion entities, allowing for a broader range of target screening, including challenging targets that are difficult to purify. Their DEL technology has evolved into DEL 2.0, which facilitates live-cell screening without the need for target protein expression and purification, thereby enhancing the relevance of the screening process to real biological environments.

NewDEL Biotech is also advancing its technology with the development of SmartDEL (DEL 3.0), an AI-powered platform that leverages big data for drug discovery. This innovative approach aims to further enhance the efficiency and success rates of drug development. The company is committed to overcoming key technological bottlenecks in the biopharmaceutical industry and aims to create a collaborative innovation ecosystem. With over 20 drug candidates in development and several projects in clinical trial phases, NewDEL Biotech is positioned to become a leading player in the global pharmaceutical landscape, focusing on making effective medications accessible to the public.

China

NewDEL Biotech is a biotechnology company based in Shenzhen, China, established in 2021. The company focuses on the research and development of new drugs, with a particular emphasis on innovative drugs designed for tumors. NewDEL Biotech utilizes DNA Encoded Library technology to significantly improve the success rate of drug development.

Newdel Biotech

Company Details